REIN registry, Agence de la biomédecine, Saint-Denis La Plaine France.
Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France.
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii60-ii67. doi: 10.1093/ndt/gfw386.
The restricted mean survival time (RMST) estimates life expectancy up to a given time horizon and can thus express the impact of a disease. The aim of this study was to estimate the 15-year RMST of a hypothetical cohort of incident patients starting renal replacement therapy (RRT), according to their age, gender and diabetes status, and to compare it with the expected RMST of the general population.
Using data from 67 258 adult patients in the French Renal Epidemiology and Information Network (REIN) registry, we estimated the RMST of a hypothetical patient cohort (and its subgroups) for the first 15 years after starting RRT (cRMST) and used the general population mortality tables to estimate the expected RMST (pRMST). Results were expressed in three different ways: the cRMST, which calculates the years of life gained under the hypothesis of 100% death without RRT treatment, the difference between the pRMST and the cRMST (the years lost), and a ratio expressing the percentage reduction of the expected RMST: (pRMST - cRMST)/pRMST.
Over their first 15 years of RRT, the RMST of end-stage renal disease (ESRD) patients decreased with age, ranging from 14.3 years in patients without diabetes aged 18 years at ESRD to 1.8 years for those aged 90 years, and from 12.7 to 1.6 years, respectively, for those with diabetes; expected RMST varied from 15.0 to 4.1 years between 18 and 90 years. The number of years lost in all subgroups followed a bell curve that was highest for patients aged 70 years. After the age of 55 years in patients with and 70 years in patients without diabetes, the reduction of the expected RMST was >50%.
While neither a clinician nor a survival curve can predict with absolute certainty how long a patient will live, providing estimates on years gained or lost, or percentage reduction of expected RMST, may improve the accuracy of the prognostic estimates that influence clinical decisions and information given to patients.
限制平均生存时间(RMST)可估计到特定时间点的预期寿命,从而可以反映疾病的影响。本研究旨在根据年龄、性别和糖尿病状态,估计起始接受肾脏替代治疗(RRT)的假设队列中患者的 15 年 RMST,并与普通人群的预期 RMST 进行比较。
利用法国肾脏流行病学和信息网络(REIN)登记处 67258 名成年患者的数据,我们估计了 RRT 起始后前 15 年的假设患者队列(及其亚组)的 RMST(cRMST),并使用普通人群死亡率表估计了预期 RMST(pRMST)。结果以三种不同方式表示:cRMST,即假设未经 RRT 治疗 100%死亡情况下的生存年数;pRMST 与 cRMST 之间的差值(损失的年数);以及表示预期 RMST 减少百分比的比值:(pRMST-cRMST)/pRMST。
在 RRT 的前 15 年中,ESRD 患者的 RMST 随年龄增长而下降,年龄 18 岁且无糖尿病的患者为 14.3 年,年龄 90 岁的患者为 1.8 年,年龄 18 岁且有糖尿病的患者为 12.7 年至 1.6 年,年龄 18 岁至 90 岁之间的预期 RMST 从 15.0 年到 4.1 年不等。所有亚组中损失的年数都呈钟形曲线分布,70 岁患者的损失年数最高。在有糖尿病的患者中,年龄超过 55 岁和无糖尿病的患者中年龄超过 70 岁后,预期 RMST 的减少率超过 50%。
虽然临床医生和生存曲线都不能绝对确定地预测患者的生存时间,但提供生存年数的增加或减少或预期 RMST 的百分比减少的估计值,可能会提高影响临床决策和向患者提供信息的预后估计的准确性。